First Time Loading...

Cardiff Oncology Inc
NASDAQ:CRDF

Watchlist Manager
Cardiff Oncology Inc Logo
Cardiff Oncology Inc
NASDAQ:CRDF
Watchlist
Price: 3.46 USD -1.7% Market Closed
Updated: May 7, 2024

Cardiff Oncology Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cardiff Oncology Inc
Cash from Operating Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Cardiff Oncology Inc
NASDAQ:CRDF
Cash from Operating Activities
-$30.9m
CAGR 3-Years
-24%
CAGR 5-Years
-19%
CAGR 10-Years
-15%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$22.8B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$8B
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$8.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.5B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.7B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
24%

See Also

What is Cardiff Oncology Inc's Cash from Operating Activities?
Cash from Operating Activities
-30.9m USD

Based on the financial report for Dec 31, 2023, Cardiff Oncology Inc's Cash from Operating Activities amounts to -30.9m USD.

What is Cardiff Oncology Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-15%

Over the last year, the Cash from Operating Activities growth was 9%. The average annual Cash from Operating Activities growth rates for Cardiff Oncology Inc have been -24% over the past three years , -19% over the past five years , and -15% over the past ten years .